Brivudine

DB03312ApprovedInvestigationalSmall molecule

Brivudine is a drug used to treat herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries.

Mechanism: Pharmacologically active on Thymidine kinase 2, mitochondrial and DNA polymerase
Curator reviewed
Formula / weight: C₁₁H₁₃BrN₂O₅ · 333.135 g/mol (avg)
Code names: RP-101

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyODZBBRURCPAEIQ-PIXDULNESA-NSMILESOC[C@H]1O[C@H](C[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O

Targets

What you can answer from here — as of September 23, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

15Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

8ContraindicationsEach with its own population and attribute set

12Marketed productsAcross 3 countries and 5 labellers

1ATC codeIncluding every combination product, plus 12 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Brivudine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.